Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company (PG) files a wide range of documents with the U.S. Securities and Exchange Commission, providing detailed insight into its operations, capital structure, governance, and shareholder policies. As a New York Stock Exchange‑listed issuer with common stock and multiple series of notes registered under Section 12(b) of the Exchange Act, P&G uses SEC filings to report material events, financing activities, executive and director matters, and shareholder meeting results.
Recent Form 8‑K filings illustrate the types of information investors can find. Regulation FD 8‑Ks document quarterly dividend declarations on common stock and ESOP convertible preferred stock, along with the company’s long record of consecutive dividend payments and increases. Other 8‑Ks report underwritten public offerings of U.S. dollar, euro, and pound sterling notes with various maturities, including floating rate notes and fixed‑rate notes issued under a shelf registration statement on Form S‑3, with related legal opinions filed as exhibits.
Additional 8‑Ks address governance topics such as the approval of The Procter & Gamble 2025 Stock and Incentive Compensation Plan, voting results from the Annual Meeting of Shareholders, and retirement announcements for senior executives. Earnings‑related 8‑Ks furnish quarterly results, slides used on earnings calls, and notices of webcasts. Together with the company’s proxy statement on Schedule 14A, these filings give a structured view of P&G’s executive compensation framework, board composition, and strategic priorities.
On this page, Stock Titan provides real‑time access to Procter & Gamble’s SEC filings as they appear on EDGAR, along with AI‑powered summaries to help explain the significance of each document. Users can quickly review annual and quarterly reports, current reports on Form 8‑K, and exhibits related to new debt offerings or compensation plans, as well as monitor items such as dividend announcements and shareholder vote outcomes without reading every page of the underlying filings.
Jennifer L. Davis, listed as CEO - Health Care at Procter & Gamble (PG), reported transactions dated 10/01/2025. The Form 4 shows a disposition of 64,990.9326 shares of common stock and an indirect holding of 15,535.3029 shares held by a retirement plan trustee. The filing also reports an acquisition of 68,869 stock options at an exercise price of $153.18; those options are listed as exercisable beginning 09/29/2028 with an expiration date of 10/01/2035.
The form includes an explanatory note that the indirect amount reflects an adjustment to the participant service trust through 09/30/2025. The document is signed on behalf of Ms. Davis by an attorney-in-fact on 10/02/2025. All items reported are changes in beneficial ownership as required under Section 16.
Matthew W. Janzaruk, SVP and Chief Accounting Officer of Procter & Gamble Co (PG), reported transactions dated 10/01/2025. He exercised_stock_options to acquire 13,779 shares (stock option exercise price $153.18) and directly holds those 13,779 shares following the exercise. The Form 4 also shows a sale of 1,703.9031 shares on the same date and reports 3,293.5342 shares beneficially owned indirectly via a retirement plan trustee after an adjustment through 9/30/2025. The filing was signed by an attorney-in-fact on 10/02/2025. The report is an insider disclosure of option exercise, a small open-market sale, and an adjustment to retirement-plan holdings; it contains transaction dates, amounts, and the exercise price but no cash proceeds or reasons for the transactions.
Procter & Gamble officer Keith R. Alexandra reported changes in beneficial ownership on a Form 4 covering transactions dated 10/01/2025. The filing shows a disposition of 27,529.5056 shares of common stock and indirect holdings reported as 4,479.8913, 4,895.7069, and 2,594.244 shares held via spouse and retirement plan trustee arrangements. The filing also reports two stock option acquisitions executed on 10/01/2025: 62,338 options exercisable from 09/29/2028 through 10/01/2035 (direct) and 14,163 options with the same exercisability and expiration terms (indirect by spouse). An explanatory note states the spouse/plan amounts reflect an adjustment through 09/30/2025. The form is signed by an attorney-in-fact on 10/02/2025.
Form 144 filed for Procter & Gamble (PG): an insider has notified the SEC of a proposed sale of 2,864 shares of Common Stock, with an aggregate market value of $435,628.72, scheduled approximately for 10/02/2025 on the NYSE. The shares were originally acquired as Restricted Stock Unit awards on 10/03/2022 totaling 5,341 units. The filer also reported prior sales in the last three months: 1,000 shares sold on 08/29/2025 for $156,835.00 and 6,167 shares sold on 08/19/2025 for $969,907.52. The notice includes the standard certification that the seller is not aware of undisclosed material adverse information.
Form 144: This notice reports a proposed sale of 3,837 shares of Common Stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $583,626.89 and an approximate sale date of 10/02/2025. The securities were acquired as a Restricted Stock Unit Award from The Procter & Gamble Company on 10/03/2022 (7269 units noted). The filing also discloses a sale within the past three months: 8,596 shares sold on 08/19/2025 for gross proceeds of $1,351,925.58. The issuer's outstanding shares are listed as 2,342,371,488. The signer affirms no undisclosed material adverse information.
Form 144 filing for Procter & Gamble (PG). An insider proposes to sell 4,739 shares of Common Stock through Morgan Stanley Smith Barney on 10/02/2025, with an aggregate market value of $720,825.60. The securities were acquired as a Restricted Stock Unit award on 10/03/2022 (9,750 units originally granted). The filer previously sold 13,039 shares on 08/19/2025 for gross proceeds of $2,050,693.08. The filing includes the standard representation that the signer is not aware of undisclosed material adverse information.
Procter & Gamble (PG) Form 144 filing reports a proposed sale of 4,203 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $639,297.32 and an approximate sale date of 10/02/2025 on the NYSE. The securities were acquired as Restricted Stock Unit awards on 10/03/2022 totaling 7,756 shares. The filer also disclosed a sale during the past three months: 10,194 shares sold on 08/21/2025 for gross proceeds of $1,612,272.85. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 notice filed for Procter & Gamble (PG) reporting a proposed sale of 13,893 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $2,113,194.77 and an approximate sale date of 10/02/2025. The filing shows the shares were acquired as a Restricted Stock Unit award on 10/03/2022 (28,235 units). It also discloses a prior sale by the same person of 40,119 shares on 08/19/2025 for gross proceeds of $6,309,667.58. The filer attests there is no undisclosed material adverse information and includes standard Rule 144 representations.
Procter & Gamble (PG) filed a Form 144 notifying the proposed sale of common stock by an insider. The notice lists two proposed transactions through Morgan Stanley Smith Barney totaling 2,680 shares with an aggregate market value of $407,641.40, each scheduled for 10/02/2025 on the NYSE. The securities were acquired as Restricted Stock Unit awards from The Procter & Gamble Company on 10/03/2022 (amounts: 874 and 4,070 units). The filing also discloses prior sales by the same person during the past three months totaling 11,463 shares that generated $1,812,976.84. The filer certifies no undisclosed material adverse information.
Form 144 notice for Procter & Gamble (PG) shows a proposed sale of 582 shares of common stock through Morgan Stanley Smith Barney on the NYSE with an approximate sale date of 10/02/2025 and an aggregate market value of $88,525.11. The securities were acquired as a Restricted Stock Unit award on 10/03/2022 from The Procter & Gamble Company, with 1,901 shares recorded as acquired. The filer previously sold 606 shares on 08/19/2025 for gross proceeds of $95,307.92. The filer affirms no undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Procter & Gamble (PG)?
What is the market cap of Procter & Gamble (PG)?
